568 COST‐UTILITY ANALYSIS EVALUATING THE LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN FOR POST‐HERPETIC NEURALGIA IN SPAIN | Publicación